%0 Journal Article
%T SARS-COV-2 Induce Pulmonary Injury from Basic to Clinical Research
%A Jinguo Zhu
%J World Journal of Cardiovascular Diseases
%P 168-190
%@ 2164-5337
%D 2022
%I Scientific Research Publishing
%R 10.4236/wjcd.2022.123018
%X The SARS-CoV-2 has infected over 194,909,000 cases and over 4,170,000 deaths in the world before the end of July 2021. The virus attacks human alveoli and induces severe lung injury (COVID-19 disease) and spreads rapidly. The mechanisms of COVID-19 disease are unclear. To better understand this disease, This review analyzes the SARS-CoV-2 biological characteristics, insights the effect of alveolar epithelium and its adjacent microvascular endo</span><span style=\"font-family:&quot;font-size:13.3333px;white-space:normal;\">thelium, investigates human host cells immune response and immunothro</span><span style=\"font-family:&quot;font-size:13.3333px;white-space:normal;\">mbosis. Explains clinical manifestations of COVID-19 associated lung injury. It may be helpful for development management strategies for COVID-19 associated pulmonary damage.
%K COVID-19
%K SARS-CoV-2
%K Pulmonary Injury
%K Clinical Manifestation
%K Treatment Strategies
%U http://www.scirp.org/journal/PaperInformation.aspx?PaperID=116331